Prosetta, antiviral-drug developer, raises $2M

Want to master the CMO role? Join us for GrowthBeat Summit on June 1-2 in Boston, where we'll discuss how to merge creativity with technology to drive growth. Space is limited and we're limiting attendance to CMOs and top marketing execs. Request your personal invitation here!

Prosetta, a San Francisco developer of new antiviral therapies, raised $2 million in early financing, VentureWire reports (subscription required). The company termed the funding a “series AAA” round that has the same terms as its earlier $1 million “series A” and $5 million “series AA” financings, but different valuations. Individual investors provided the entire funding, which values the company at over $20 million.

Prosetta, founded by Vishwanath Lingappa, Jaisri Lingappa and other UCSF academics, is working on small-molecule drugs — that is, compounds that can be taken orally — to disrupt the protein coats, or capsids, that viruses form to protect their genes. The company’s first candidate will target hepatitis C.


VentureBeat’s VB Insight team is studying email marketing tools. Chime in here, and we’ll share the results.